Abstract
Changes associated with neurodegeneration at the cellular level are manifestations of deregulated biochemical pathways, and typically precede neuronal loss. Incorporation of molecular markers in the diagnostic process could aid detection of early changes, prior to extensive neuronal loss, as early as the presymptomatic stages of the disorder, thus enabling improved patient stratification for targeted drug development. Such biomarkers should be sufficiently sensitive and specific to distinguish AD from other disorders with overlapping symptoms. Easily accessible biosamples, simple methodology, and low overall cost would enable population screening, which would not be feasible with other modalities. Non-coding (nc)RNAs have a crucial role in the entire spectrum of cellular processes, from development and differentiation to homeostatic maintenance, and have been implicated in different diseases; micro-RNAs (miRNAs) are a family of ncRNA molecules with an important role in posttranscriptional gene silencing. The early advances in the study of miRNAs as noninvasive biomarkers in cancer inspired their study for other conditions, including AD. Several deregulated miRNAs in brain, CSF, and blood have been associated with AD and other brain disorders. Their high stability makes miRNAs attractive for biomarker development, and a number of platforms are currently available for their analysis. qPCR is a technology characterized by high sensitivity and is suitable for focused analysis of specific candidates (assays) in a large number of samples. Microfluidic-based qPCR platforms have minimal RNA requirements and can yield thousands of datapoints in one qPCR experiment. Here, I present the use of miScript qPCR miRNA assays with the Fluidigm BioMark HD System.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Grasso M, Piscopo P, Confaloni A, Denti MA (2014) Circulating miRNAs as biomarkers for neurodegenerative disorders. Molecules 19(5):6891–6910. https://doi.org/10.3390/molecules19056891
Schneider A, Simons M (2013) Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res 352(1):33–47. https://doi.org/10.1007/s00441-012-1428-2
He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5(7):522–531. https://doi.org/10.1038/nrg1379
Kozomara A, Griffiths-Jones S (2014) miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 42(Database issue):D68–D73. https://doi.org/10.1093/nar/gkt1181
Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD, Richards CA (2008) Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14(1):27–41
Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM, Sczakiel G (2010) A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28(6):655–661. https://doi.org/10.1016/j.urolonc.2009.01.027
Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG, Alevizos I (2010) Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis 16(1):34–38. https://doi.org/10.1111/j.1601-0825.2009.01604.x
Xing L, Todd NW, Yu L, Fang H, Jiang F (2010) Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol 23(8):1157–1164. https://doi.org/10.1038/modpathol.2010.111
Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127(1):118–126. https://doi.org/10.1002/ijc.25007
Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce CM, Pastorino U, Sozzi G (2011) MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 108(9):3713–3718. https://doi.org/10.1073/pnas.1100048108
Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT (2009) Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 15(17):5473–5477. https://doi.org/10.1158/1078-0432.CCR-09-0736
Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, Werner J, Hackert T, Ruprecht K, Huwer H, Huebers J, Jacobs G, Rosenstiel P, Dommisch H, Schaefer A, Muller-Quernheim J, Wullich B, Keck B, Graf N, Reichrath J, Vogel B, Nebel A, Jager SU, Staehler P, Amarantos I, Boisguerin V, Staehler C, Beier M, Scheffler M, Buchler MW, Wischhusen J, Haeusler SF, Dietl J, Hofmann S, Lenhof HP, Schreiber S, Katus HA, Rottbauer W, Meder B, Hoheisel JD, Franke A, Meese E (2011) Toward the blood-borne miRNome of human diseases. Nat Methods 8(10):841–843. https://doi.org/10.1038/nmeth.1682
Kumar S, Reddy PH (2016) Are circulating microRNAs peripheral biomarkers for Alzheimer’s disease? Biochim Biophys Acta 1862(9):1617–1627. https://doi.org/10.1016/j.bbadis.2016.06.001
Hara N, Kikuchi M, Miyashita A, Hatsuta H, Saito Y, Kasuga K, Murayama S, Ikeuchi T, Kuwano R (2017) Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer’s disease. Acta Neuropathol Commun 5(1):10. https://doi.org/10.1186/s40478-017-0414-z
Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C, Cheo D, D'Andrade P, DeMayo M, Dennis L, Derveaux S, Feng Y, Fulmer-Smentek S, Gerstmayer B, Gouffon J, Grimley C, Lader E, Lee KY, Luo S, Mouritzen P, Narayanan A, Patel S, Peiffer S, Ruberg S, Schroth G, Schuster D, Shaffer JM, Shelton EJ, Silveria S, Ulmanella U, Veeramachaneni V, Staedtler F, Peters T, Guettouche T, Wong L, Vandesompele J (2014) Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods 11(8):809–815. https://doi.org/10.1038/nmeth.3014
Zeka F, Mestdagh P, Vandesompele J (2015) RT-qPCR-based quantification of small non-coding RNAs. Methods Mol Biol 1296:85–102. https://doi.org/10.1007/978-1-4939-2547-6_9
Qiagen-GmbH (2014) RT2 Profiler PCR array handbook. QIAGEN. https://www.qiagen.com/at/resources/download.aspx?id=6161ebc1-f60f-4487-8c9e-9ce0c5bc3070&lang=en. Accessed 3 July 2017
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Takousis, P. (2018). Analysis of Micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer’s Disease Biomarker Discovery. In: Perneczky, R. (eds) Biomarkers for Alzheimer’s Disease Drug Development. Methods in Molecular Biology, vol 1750. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7704-8_19
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7704-8_19
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7703-1
Online ISBN: 978-1-4939-7704-8
eBook Packages: Springer Protocols